X.T.L. Biopharmaceuticals Overview
Valuation check: XTLB's P/E ratio is -0.78, below the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow-0.78
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, XTLB shows a P/E ratio of -0.78. That is below the Healthcare sector average of 24.78. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 24.78. X.T.L. Biopharmaceuticals is at -0.78, which is lower that average. That is roughly 103.1% below the sector mean. Use the comparison chart on this page to see how XTLB stacks up against individual peers as well.
Investors watch XTLB's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. X.T.L. Biopharmaceuticals's latest reading is -0.78. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has X.T.L. Biopharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -0.78) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 24.78, while XTLB is at -0.78. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
